Key result
Transapical off-pump mitral repair linked to lower morbidity but ~12% residual MR versus conventional repair.
Why the study?
Transapical off-pump implantation of artificial chordae has gained interest for degenerative mitral regurgitation, but studies comparing its results with conventional mitral valve repair were lacking.
Does transapical off-pump implantation of artificial chordae improve early postoperative outcomes compared to conventional mitral valve repair in patients with degenerative mitral regurgitation?
Cohort (n=169)
No
Does transapical off-pump implantation of artificial chordae improve early postoperative outcomes compared to conventional mitral valve repair in patients with degenerative mitral regurgitation?
Answers are grounded in this paper and cite their sources.
Transapical off-pump mitral valve repair is associated with lower early postoperative morbidity but a higher risk of residual moderate to severe mitral regurgitation compared to conventional repair.
Introduction: Conventional mitral valve repair (CMVR) is well-established, safe and effective treatment for degenerative mitral regurgitation (MR).Transapical off-pump implantation of artificial chordae (TA) has been introduced into practice and gained interest among surgeons.However, there are no publications comparing the results between TA and CMVR.Aim: To compare early postoperative outcomes of CMVR with TA in patients with degenerative MR. Material and methods:This was a retrospective cohort study.A total of 169 patients who underwent mitral valve repair between 2011 and 2018 were included in this analysis.Patients were divided into two groups: the TA group, n = 78 and CMVR group, n = 91.The groups were compared for early postoperative outcomes.Results: Patients in the TA group were younger, 54.2 ±11.1 vs. 59.5 ±12.8 years (p = 0.005).Patients in the CMVR group had more complicated postoperative course with higher incidence of blood transfusion (42.9% vs. 7.8%, p = 0.001), atrial fibrillation (25.3% vs. 11.7%,p = 0.031), renal insufficiency (15.4% vs. 2.6%, p = 0.007) and stroke (2.1% vs. 0%).In the early postoperative period, one patient died in the TA group, and there were no deaths in the CMVR group (p = 0.277).Residual moderate to severe mitral regurgitation was present in nine (11.5%) TA patients, while none of the patients in the CMVR group had moderate or a higher degree of residual regurgitation (p = 0.001).Conclusions: Off-pump transapical MV repair is a feasible and safe procedure with low postoperative morbidity rates.Higher rates of mitral regurgitation reoccurrence would require a careful and thorough selection of the patients suitable for the TA approach.
No takes yet. Share an insight, caveat, or question.
Zorinas et al. (2019) conducted a cohort in Severe degenerative mitral valve disease (n=169). Transapical off-pump mitral valve repair vs. Conventional mitral valve repair was evaluated on Residual moderate to severe mitral regurgitation at 30 days (p=0.001). Transapical off-pump mitral valve repair was associated with lower postoperative morbidity but a higher rate of residual moderate to severe mitral regurgitation compared to conventional repair.
Synapse has enriched 10 related papers. Consider them for comparative context: